Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:BOLD

Audentes Therapeutics (BOLD) Stock Price, News & Analysis

Audentes Therapeutics logo

About Audentes Therapeutics Stock (NASDAQ:BOLD)

Key Stats

Today's Range
$2.94
$3.00
50-Day Range
$59.97
$59.97
52-Week Range
$22.00
$60.00
Volume
28,904 shs
Average Volume
61,736 shs
Market Capitalization
$66.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.00
Consensus Rating
Buy

Company Overview

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.

Audentes Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
40th Percentile Overall Score

BOLD MarketRank™: 

Audentes Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 717th out of 976 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Audentes Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Audentes Therapeutics has received no research coverage in the past 90 days.

  • Read more about Audentes Therapeutics' stock forecast and price target.
  • Percentage of Shares Shorted

    1.88% of the float of Audentes Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Audentes Therapeutics has a short interest ratio ("days to cover") of 4.2.
  • Change versus previous month

    Short interest in Audentes Therapeutics has recently decreased by 51.37%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Audentes Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Audentes Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.88% of the float of Audentes Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Audentes Therapeutics has a short interest ratio ("days to cover") of 4.2.
  • Change versus previous month

    Short interest in Audentes Therapeutics has recently decreased by 51.37%, indicating that investor sentiment is improving significantly.
    Receive BOLD Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Audentes Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    BOLD Stock News Headlines

    Crypto Crash Ahead? (27 Experts Weigh In)
    Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!
    Boundless Bio Inc. Common Stock
    See More Headlines

    BOLD Stock Analysis - Frequently Asked Questions

    Audentes Therapeutics Inc (NASDAQ:BOLD) released its earnings results on Monday, August, 12th. The biotechnology company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.03.

    Audentes Therapeutics (BOLD) raised $100 million in an initial public offering (IPO) on Thursday, March 28th 2024. The company issued 6,250,000 shares at a price of $16.00 per share.

    Audentes Therapeutics' lock-up period expired on Tuesday, September 24th. Audentes Therapeutics had issued 6,250,000 shares in its IPO on March 28th. The total size of the offering was $100,000,000 based on an initial share price of $16.00. Since the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Audentes Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Alphabet (GOOG) and Visa (V).

    Company Calendar

    Last Earnings
    8/12/2024
    Today
    11/02/2024
    Next Earnings (Estimated)
    11/11/2024
    Fiscal Year End
    12/31/2024

    Industry, Sector and Symbol

    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    N/A
    Current Symbol
    NASDAQ:BOLD
    Fax
    N/A
    Employees
    207
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $23.00
    High Stock Price Target
    $25.00
    Low Stock Price Target
    $20.00
    Potential Upside/Downside
    +671.8%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    3 Analysts

    Profitability

    Pretax Margin
    N/A

    Debt

    Sales & Book Value

    Annual Sales
    N/A

    Miscellaneous

    Free Float
    21,075,000
    Market Cap
    $66.31 million
    Optionable
    No Data
    Beta
    N/A
    7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

    As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

    Get This Free Report

    This page (NASDAQ:BOLD) was last updated on 11/2/2024 by MarketBeat.com Staff
    From Our Partners